MetaCap

IGC Pharma (IGC) vs TransCode Therapeutics (RNAZ)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

IGC Pharma (IGC) has outperformed TransCode Therapeutics (RNAZ) over the past year, losing 47.5% versus a loss of 86.6%. Over five years, IGC leads with a -87.6% price change compared with -100.0% for RNAZ. TransCode Therapeutics is the larger company by market cap ($20.1 million vs $19.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IGC-47.50%RNAZ-86.57%
+49%-22%-93%
Nov 21, 20251 yearNov 20, 2026
IGC-88.25%RNAZ-100.00%
+17%-45%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IGC versus RNAZ key metrics
MetricIGCRNAZ
Share price$0.168$1.16
Market cap$19.60M$20.07M
1-day change-8.70%-10.77%
YTD return-40.00%-83.02%
1-year return-47.50%-86.57%
5-year return-87.65%-100.00%
EPS (TTM)$-0.07$-47.95
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.27M—
Revenue growth (YoY)-5.50%—
Net income (latest FY)$-7.12M$-34.66M
Gross margin48.70%—
Operating margin-585.84%—
Net margin-560.35%—
52-week high$0.36$12.60
52-week low$0.08$1.01
Distance from 52-week high-53.33%-90.79%
Analyst consensusnone—
Avg. price target upside+3471.43%—
Average volume615.25K52.03K
Shares outstanding116.69M17.30M
Employees7012
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IGC has outperformed RNAZ by 39.1 percentage points over the past year.

About IGC Pharma

IGC stock →

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's.

Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees

About TransCode Therapeutics

RNAZ stock →

TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

IGC vs RNAZ FAQ

Which is bigger, IGC Pharma or TransCode Therapeutics?

TransCode Therapeutics (RNAZ) is larger, with a market capitalization of $20.07M compared with $19.60M for IGC Pharma (IGC).

Which stock has performed better over the past year, IGC or RNAZ?

IGC returned -47.50% over the past 12 months, compared with -86.57% for RNAZ (price return, excluding dividends). Past performance does not predict future results.

Are IGC Pharma and TransCode Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons